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In late-onset Alzheimer’s disease (AD),multiple brain regions are not affected simultaneously. Comparing the gene expression of the
affected regions to identify the differences in the biological processes perturbed can lead to greater insight into AD pathogenesis
and early characteristics. We identified differentially expressed (DE) genes from single cell microarray data of four AD affected
brain regions: entorhinal cortex (EC), hippocampus (HIP), posterior cingulate cortex (PCC), and middle temporal gyrus (MTG).
We organized the DE genes in the four brain regions into region-specific gene coexpression networks. Differential neighborhood
analyses in the coexpression networks were performed to identify genes with low topological overlap (TO) of their direct neighbors.
The low TO genes were used to characterize the biological differences between two regions. Our analyses show that increased
oxidative stress, along with alterations in lipid metabolism in neurons, may be some of the very early events occurring in AD
pathology. Cellular defense mechanisms try to intervene but fail, finally resulting in AD pathology as the disease progresses.
Furthermore, disease annotation of the low TO genes in two independent protein interaction networks has resulted in association
between cancer, diabetes, renal diseases, and cardiovascular diseases.
1. Introduction
Late-onset Alzheimer’s disease (LOAD) is a multigene neu-
rodegenerative disorder of the brain and is the commonest
form of dementia. Pathologically AD is characterized by the
presence of neurofibrillary tangles (NFT) in the neurons and
the deposition of amyloid-𝛽 (A𝛽) plaques. Several processes
have been associated with AD, such as inflammation, loss of
neurons, synaptic pathology, calcium dysregulation, choles-
terol synthesis, reentry into the cell cycle, and oxidative stress.
Certain brain regions have shown increased susceptibilities to
the pathological and metabolic characteristics of AD [1–5].
Analyzing the variations in the transcriptome of the affected
brain regions to identify the differences in the biological
pathways or processes perturbed in AD can lead to greater
insight into its pathogenesis and progression.
Alzheimer’s disease affects multiple brain regions but
begins in the entorhinal cortex (EC) and hippocampus (HIP)
[6]. Other brain regions such as the middle temporal gyrus
(MTG) and the posterior cingulate cortex (PCC) get affected
later during the course of the disease [6, 7]. In the data
analyzed in this report, samples (neurons only) that were
collected from the PCC and MTG would be from brains that
already have AD in the EC andHIP. As shown in Figure 1, the
amount of degeneration in the PCC and MTG may not be as
severe as in the EC and HIP.
In this study, we employ a novel differential network
topology method to examine these four AD affected brain
regions for differences in biological processes affected in
the disease. We use graph theory methods to analyze the
low TO nodes (genes) in a gene coexpression network
corresponding to different brain regions affected in AD. The
coexpression network was built from differentially expressed
genes identified from samples consisting of homogeneous
cell population of neurons. We extract the low TO genes
from gene coexpression networks, which represent different
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Figure 1: Sample collection and degenerative processes. This figure
shows how different brain regions (EC: entorhinal cortex; HIP:
hippocampus; PCC: posterior cingulate cortex; MTG: middle tem-
poral gyrus) get affected with degenerative processes over time.The
figure is not drawn to scale. Exactly when each set of degenerative
processes (as indicated by the white, yellow, and red colors) begins
in the different brain regions and how long they last in each region
is unknown. This figure shows the logic used in this analysis—that
when tissue is collected at the time shown, the PCC and MTG
regions which get affectedmuch later in Alzheimer’s will have initial
or very early degenerative processes as compared to the HIP and
EC. The late stage processes will slowly dominate the brain region
and, therefore, it will be difficult to identify early AD processes with
statistical significance in the EC and HIP.
brain regions, to identify the biological processes that may be
involved in early AD. We postulate that these selected low
TO genes may contribute to the difference in the response
to the disease in different brain regions. Furthermore, we
identified the diseases associated with low TO genes and
neighborhoods in two separate protein-protein interaction
(PPI) networks. Finally, we suggest a possible sequence of
biological phenomena thatmay characterize ADprogression.
Our goal is to leverage insights to better understand processes
involved in early Alzheimer’s that may be the cause of
neurodegeneration.The complete analysis approach is shown
in Figure 2.
2. Materials and Methods
2.1. Expression Data. For our analyses we used microarray
(Affymetrix Human Genome U133 Plus 2.0) expression data
obtained via laser captured microdissection and data from
different brain regions that are either histopathologically or
metabolically relevant to Alzheimer’s disease (AD) (GEO
accession number GSE5281) [1]. Brain samples were from
clinically classified late-onset AD patients and normal con-
trols of either sex. The mean age at death was 79.9 ± 6.9
years. Data included expression profiles from the entorhinal
cortex (EC; Brodmann area (BA) 28 and 34), hippocampus
(HIP; CA1 region), middle temporal gyrus (MTG; BA 21
and 37), and posterior cingulate cortex (PCC; BA 23 and
31). The EC and HIP are affected by intracellular neurofib-
rillary tangles, and the MTG and PCC are preferentially
affected by metabolism and extracellular amyloid-𝛽 plaques
[1]. Alzheimer’s affected subjects had a Braak stage ranging
from III to VI [6] with a Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD) neuritic plaque density
of moderate or frequent. The expression data was obtained
from approximately 500 non-tangle-bearing cortical pyrami-
dal neurons from AD afflicted subjects for direct compar-
ison with non-tangle-bearing neurons from neurologically
healthy individuals of the control group.The data consisted of
13 control subjects and 10 AD individuals for EC, 13 control
subjects and 10 AD individuals for HIP, 12 control subjects
and 16 AD individuals for MTG, and 13 control subjects and
9 AD individuals for PCC. For further information regarding
this data, please refer to [1].
Probe sets were normalized using the GC robust mul-
tiarray average (GC-RMA) algorithm and processed for
differential expression by using the two-class significance
analysis of microarrays (SAM) [8]. SAM uses a modified 𝑡-
statistics method to identify DE genes. Within each brain
region, AD affected subjects and normal controls were
compared to identify differentially expressed (DE) genes.
Differentially expressed (DE) genes refer to those genes that
have a difference in their mRNA expression level between
the affected and control groups. We used DAVID to perform
functional annotation clustering (similarity threshold = 0.80)
based on diseases associated, if any, with the genes [9].
2.2. Coexpression Networks Creation. Gene coexpression
networks were built by connecting genes whose pairwise
expression similarity using the Pearson correlation coefficient
(PCC) was at or above a threshold 𝑡. For two genes to be
considered as coexpressed, their expression profiles need to
satisfy at least one of the following conditions: (1) their cor-
relation coefficient is higher than 0.3, and one gene is ranked
as the top 3 most correlated genes of the other; (2) the corre-
lation coefficient between them is higher than a user defined
Pearson correlation coefficient threshold 𝑡 (𝑡 = 0.7 in all the
networks constructed here) and one gene is within the top 50
most correlated genes of the other [10].The coexpression net-
work construction is described in detail in [10].Themain rea-
son for choosing a small PCC cut-off of 0.3 is that as the PCC
increases the number of nodes with no links also increases
(see Figure 1 in [10]).We constructed a coexpression network
with no isolated nodes. Also, we chose to connect the nodes
with PCC of 0.3 only to 3 nodes since the median number of
links is very high for nodes with a low PCC and that would
result in too many unnecessary links with low PCC (see
Figure 1 in [10]).This approach resulted in a sparse, fully con-
nected, unweighted, and undirected coexpression network.
The coexpression network is represented as a binary adja-
cency matrix with 0 referring to no link between two genes
and 1 corresponding to a link between the genes.This network
method has had other successful applications [11–14].
A coexpression network was constructed for a brain
region under investigation using the differentially expressed
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Figure 2: Analyses flowchart. The top half of the figure (above the dashed line) shows how the genes with low topological overlap (low
TO genes) are selected and then analyzed for association with biological processes and diseases. The bottom half of the figure shows all the
comparisons with the protein-protein interaction (PPI) networks. The region PPI network was created using our set of low TO genes as seed
nodes. Since there were six regional comparisons, there resulted six region PPI networks. For each of the 6 regional comparisons, a pair of
low TO gene modules was created. One low TO gene module contained the low TO genes that had a higher connectivity in a certain region
(say R1) and their direct neighbors in the R1-R2 region PPI network and the other low TO gene module contained the low TO genes that had
a higher connectivity in the other region (R2) and their direct neighbors in the R1-R2 region PPI network. The Soler-Lo´pez AD PPI network
was reconstructed from the report by Soler-Lo´pez et al. The low TO genes from our analyses were mapped onto the Soler-Lo´pez AD PPI
network for the creation of the pair of low TO gene modules. The creation of the pair of low TO gene modules was the same as before except
that this time the neighbors were selected from the Soler-Lo´pez AD PPI network.
4 International Journal of Alzheimer’s Disease
(DE) genes that were common to two brain regions and using
the samples (control and affected) of that specific region (see
Figure 1 (top half) and Figure 2). This approach resulted in
six comparisons of brain regions: EC with HIP (EC-HIP), EC
with MTG (EC-MTG), EC with PCC (EC-PCC), HIP with
MTG (HIP-MTG), HIPwith PCC (HIP-PCC), and PCCwith
MTG (PCC-MTG), as shown in Figure 2.
2.3. Topological Overlap between Coexpression Networks. Let
coexpression networks network 1 and network 2 correspond
to brain regions 1 and 2, respectively. Since network 1 and
network 2 were built using the common DE genes between
regions 1 and 2, the networks have the same set of nodes/genes
but different connections. A node/gene in the network is
denoted by 𝑔𝑒𝑛𝑒
𝑖
where 𝑖 = 1, 2, . . . , 𝑚 and 𝑚 is the total
number of nodes in the network.
The sets of genes connected to 𝑔𝑒𝑛𝑒
𝑖
in network 1 and
network 2 are 𝑋
𝑖1
and 𝑋
𝑖2
, respectively. The topological
overlap (TO) for 𝑔𝑒𝑛𝑒
𝑖
between network 1 and network 2 is
TO
𝑖
=
󵄨󵄨󵄨󵄨𝑋𝑖1⋂𝑋𝑖2
󵄨󵄨󵄨󵄨 + 1
max (󵄨󵄨󵄨󵄨𝑋𝑖1
󵄨󵄨󵄨󵄨 ,
󵄨󵄨󵄨󵄨𝑋𝑖2
󵄨󵄨󵄨󵄨)
⋅
1
√󵄨󵄨󵄨󵄨𝑋𝑖1
󵄨󵄨󵄨󵄨 ⋅
󵄨󵄨󵄨󵄨𝑋𝑖2
󵄨󵄨󵄨󵄨
,
1
𝑑2
𝑖
≤ TO
𝑖
≤
𝑑
𝑖
+ 1
𝑑2
𝑖
, where 𝑑
𝑖
= max (󵄨󵄨󵄨󵄨𝑋𝑖1
󵄨󵄨󵄨󵄨 ,
󵄨󵄨󵄨󵄨𝑋𝑖2
󵄨󵄨󵄨󵄨) .
(1)
The above formula is a modification of our previous
topological overlap formula described in [11, 12].The formula
ranks genes based on its (i) neighborhood size and (ii)
difference between neighborhoods in the two regional coex-
pression networks. We wanted to identify genes that have not
only low neighborhood overlap but also large neighborhood
size.
There are nine possible scenarios of neighborhood over-
lap as shown in Figure 4. Scenarios 1, 2, and 6 occur when
the neighborhoods of a gene in both regional networks
are large and they have either zero (scenario 1), small
(scenario 2), or large/complete (scenario 6) overlap of their
neighbors. When the gene has a large neighborhood in one
network and a small one in the other, the possible kinds
of overlap are zero (scenario 3), small (scenario 4), and
large/complete overlap (scenario 5). In scenarios 7, 8, and
9, when both neighborhoods of the gene are small, they
could have either zero (scenario 7), small (scenario 8), or
large/complete overlap (scenario 9). A gene with a large
difference in its neighborhood size and low overlap (scenario
3 and scenario 4) or one with large neighborhoods and
low overlap (scenarios 1 and 2) is very interesting, because
it implies that this gene may be active and may play a
very different role in the two regions. A gene is ranked the
highest if it has a large neighborhood but no overlap of
neighborhoods. The new low TO formula resulted in better
identification of relevant biological processes in the different
regions.
Genes were ranked according to their topological overlap
in ascending order. Brain region comparison was done using
top 10% of ranked genes (see Section 3). Since the conditions
are similar (both are AD affected, with high overlap of the
common DE genes), there is bound to be more similarities,
than differences, between the different networks. We chose
10% as there would be a small number of genes contributing
to the difference between the regions since the condition,
although similar, is still not identical. Genes with other
values of topological overlap, if properly justified, can also be
considered [11]. Comparisons against 100 random networks
(random additions or deletions of edges in the network while
keeping the total number of edges in the entire network equal
to the original network) using 𝑡-statistics were made to assess
the significance of low TO genes. All sets of low TO genes had
significance 𝑃 < 0.05 compared to random networks.
Biological analysis and interpretation of genes of interest
was performed by identifying significant biological processes
or pathways. Statistically significant biological pathways
were identified using the well annotated GeneGo MetaCore
database [15], which is a commercial tool. MetaCore is
based on a proprietary manually curated database of human
protein-protein, protein-DNA, and protein compound inter-
actions, metabolic and signaling pathways, and the effects
of bioactive molecules in gene expression [15]. We upload
a set of genes into GeneGo MetaCore module and GeneGo
checks to find which pathways are significant with a FDR
= 0.05. It compares the user’s uploaded set of genes with
the set of genes/proteins stored in their pathways database.
Significance (𝑃 values) in GeneGo of a biological pathway
is evaluated based on the size of the intersection between
user’s dataset and set of genes/proteins corresponding to a
network module/pathway in question. Thorough details of
the significance calculation are provided in [16, 17].
2.4. Eigenvector Centrality Calculation. Centrality is a func-
tion 𝐶 which assigns a numeric value to every vertex V in a
graph 𝐺, say 𝐶(V). In graph 𝐺, a vertex 𝑢 is more important
than a vertex V if and only if 𝐶(𝑢) > 𝐶(V). In social
networks, centrality is used to find the most “influential”
or “central” nodes. Among different kinds of centrality,
eigenvector centrality has been used to study epidemics as it
is the best measure of spreading power in a network [18]. An
eigenvector 𝜙 and associated eigenvalue 𝜆 are defined by
𝜆𝜙 = 𝐴𝜙, (2)
where 𝐴 is the adjacency matrix of the graph. If 𝜙 is an
eigenvector then so is 𝜅𝜙 for any 𝜅 ̸= 0. Often 𝜙 is defined
to have unit length and is then, in general, unique up to sign.
In an undirected connected graph 𝐺 = (𝑉, 𝐸), 𝑉 is the set
of vertexes/nodes with |𝑉| = 𝑛 and 𝐸 is the set of edges. Let𝐴
be its adjacency matrix, where 𝑎
𝑖𝑗
= 1, if (V
𝑖
, V
𝑗
) ∈ 𝐸; 𝑎
𝑖𝑗
= 0,
otherwise. Bonacich [19] defines eigenvector centrality of a
vertex V
𝑖
as
𝐸𝑔𝐶 (V
𝑖
) =
1
𝜆
∑
V𝑗∈𝑉
𝑎
𝑖𝑗
𝐸𝑔𝐶 (V
𝑗
) ; (3)
equivalently, let 𝑐 = (𝐸𝑔𝐶(V
1
), . . . , 𝐸𝑔𝐶(V
𝑛
)),
𝐴𝑐 = 𝜆𝑐. (4)
It has been shown that, for an adjacency matrix of an
undirected graph, there exists a nonnegative eigenvector
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(all entries are nonnegative). The entities of this nonnegative
eigenvector are centrality scores of the vertexes/nodes in𝐺. If
we normalize 𝑐 = (𝐸𝑔𝐶(V
1
), . . . , 𝐸𝑔𝐶(V
𝑛
)) under Euclidean
norm such that its Euclidean norm is ‖𝑐‖ = √2, 𝐸𝑔𝐶(V
𝑖
)
can be used for comparison among networks of different
sizes [20]. In this paper, Euclidean normalized eigenvector
centrality was calculated using the the function evcent() in the
R package igraph.
We computed the eigenvector centrality scores for (i) low
TO genes between brain regional networks; (ii) low TO genes
between affected and control networks within each brain
region (coexpression networks are built onDE genes between
the affected and control); and (iii) DE genes between affected
and control within one brain region. Construction of the
coexpression networks in (i) is explained in “Coexpression
Networks Creation.” The coexpression networks in (ii) and
(iii) are briefly explained below.
The differentially expressed genes between affected and
control samples within each region were used to build an
“affected” and a “control” coexpression network for that
brain region (a total of 8 coexpression networks). Our
topological similarity measure was applied to select genes
with low topological overlap (TO) between affected and
control coexpression networks within a brain region. Four
sets of low TO genes were obtained for four brain regions.
Then the eigenvector centrality values of these low TO genes
in the affected and control networks were computed. These
results would aid us in determining if the average eigenvector
centrality scores of the low TO genes were higher or lower
in the affected network compared to the control. Then the
eigenvector centrality scores were computed for the low
TO genes obtained by comparing brain regions in order to
determine if one region had lower/higher average eigenvector
centralities compared to the other. Welch’s 𝑡-test was used
to check whether the mean eigenvector centrality score in
one group was significantly different from the other and two-
tailed 𝑃-values were noted for all comparisons.
2.5. Protein-Protein Interaction Networks Construction.
Protein-protein interactions were obtained from the Human
Protein Reference Database (HPRD database) (March,
2012) to construct the regional protein-protein interaction
network (region PPI network). All genes were converted
to their corresponding protein products. Six protein sets
from six pairwise regional comparisons were used as seed
sets. Full PPI networks were constructed by firstly including
direct neighbors of seed proteins and then neighbors of those
neighbors until no more extra proteins could be included.
Full PPI networks were pruned such that the fewest possible
nonseed proteins were included to keep connected seeds in
the full PPI networks still connected. The pruning procedure
is briefly explained below.
Phase 1. For all connected seeds, include all extra nodes on
the shortest paths connecting those seeds.
Phase 2. For each pair of connected seeds and each shortest
path connecting them, count the number of seeds on this
shortest path. Find the maximum for one pair of connected
seeds, denoted by 𝑀. Exclude nonseed nodes from the
shortest paths that have less than𝑀 seeds.
Phase 3. For each shortest path 𝑝 passing through the first
two pruning phases, count the number of times its nonseed
node 𝑉
𝑖
appears on a shortest path connecting two seeds,
denoted by 𝑛
𝑖
. The frequency of 𝑝 is defined as 𝑁
𝑝
=
sum
𝑉𝑖 on 𝑝𝑛𝑖. For each pair of seeds, prune nonseed nodes on
the shortest paths with𝑁
𝑝
< max
𝑝 connecting seeds(𝑁𝑝).
Since all protein-protein interactions in HPRD are undi-
rected relations, the regional PPI networks in this study are
undirected networks. Supplemental information about the
detailed pruning procedure and sizes of PPI networks before
and after pruning is available upon request.
2.6. Alzheimer’s Disease Protein Network Construction. The
largest network of protein interactions related to Alzheimer’s
was reported by Soler-Lo´pez et al. [21] and referred to
as “AD PPI network.” In Soler-Lo´pez et al.’s study [21], 12
known AD associated genes (seeds) were selected. Through
yeast two-hybrid (Y2H) matrix screen and yeast two-hybrid
(Y2H) library screen, 200 interactions with high confidence
level between 74 nodes were detected, including seed-seed,
seed-candidate, and candidate-candidate interactions. A high
confidence network (HC network) regarding AD was con-
structed based on the 200 interactions. This HC network
was merged with direct interactors of 12 AD seeds from
IntAct, DIP, MINT, and HPRD. The AD network contains
1704 nodes and 5881 interactions and was stored as a binary
adjacency matrix. In our analyses, the official gene symbols
were converted to UniprotKB accession numbers and then to
Entrez gene IDs for functional annotation analysis inDAVID.
3. Results
3.1. Significant Biological Processes of Geneswith LowTopologi-
cal Overlap. Figure 1 is critical to our analyses and interpreta-
tion of the results.Through the figurewe attempt to show that,
in an AD affected individual’s brain, the entorhinal cortex
(EC) and the hippocampus (HIP) get affected much before
the posterior cingulate cortex (PCC) and themiddle temporal
gyrus (MTG). Furthermore, when a region gets affected
with the disease, the initial biological processes are different
from the final biological processes that lead to neurofibrillary
tangles and extracellular neuritic plaques associated with AD.
The knowledge of the early events in AD can help in early AD
detection, therapeutic intervention, and drug development.
We show in Figure 1 that when samples are collected from
affected PCC and MTG regions in AD affected brains, the
amount of degeneration or the kind of biological processes
may be related to early AD as opposed to late AD.
The number of differentially expressed (DE) probes per
region is shown in Table 1. Six sets of common DE genes (see
Section 2) were obtained from six comparisons: (1) entorhi-
nal cortex (EC) and hippocampus (HIP); (2) entorhinal cor-
tex (EC) and posterior cingulate cortex (PCC); (3) entorhinal
cortex (EC) and middle temporal gyrus (MTG); (4) hip-
pocampus (HIP) and posterior cingulate cortex (PCC); (5)
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Table 1: Number of differentially expressed (DE) genes and associ-
ated false discovery rate (FDR) in the four brain regions.
Region Number of DE genes (FDR)
Entorhinal cortex (EC) 5776 (0.5%)
Hippocampus (HIP) 5264 (0.5%)
Middle temporal gyrus (MTG) 3379 (0.5%)
Posterior cingulate cortex (PCC) 6536 (0.4%)
Number of common genes across 320
all four DE probe sets
Table 2: Number of genes common to the set of DE genes of
the regions being compared and the number of genes with low
topological overlap.
Comparison Number of common Number of low TO genes
DE genes (𝑃 < 1 × 10𝑒−135)
EC-HIP 2041 204
EC-MTG 1398 140
EC-PCC 2424 242
HIP-MTG 1248 125
HIP-PCC 3118 312
PCC-MTG 1582 158
hippocampus (HIP) and middle temporal gyrus (MTG); (6)
posterior cingulate cortex (PCC) and middle temporal gyrus
(MTG) (see Figure 3).
Twelve coexpression networks were built as shown in
Figure 3. Genes with low topological overlap were identified
in each regional comparison. The number of genes with low
topological overlap (TO) between different brain regions is
shown in Table 2.We derive our conclusions from 2 ideas: (1)
that the PCC and MTG get affected later in AD progression
after the EC and HIP [7, 22] (hence, studying the PCC and
MTG in brains that already have AD affected EC and HIP
will result in identifying the biological processes that occur
early in AD pathogenesis) and (2) that genes with low overlap
of their neighborhoods in the two regional networks are the
genes thatmay contribute to the biological difference between
regions in their response to AD [11, 12]. They may invoke
either different biological functions (as they are connected to
different sets of neighbors) or the same biological pathways
to varying degrees [23–26].
We show the significant biological processes for the low
TOgeneswith a higher connectivity (greater number of edges
in the coexpression network) in a certain region in Table 3.
The significant biological processes of the six sets of low TO
genes (without dividing into groups of higher connectivity)
are provided as supplemental information that is available
upon request. Since the PCC and MTG get affected later in
AD progression after the EC and HIP [7, 22], it is probable
that the processes present in the PCC and MTG occur early
in AD pathogenesis. The EC and HIP have a wide range of
processes, such as those involved in response to stress, apop-
tosis, cell cycle, immune response, postsynaptic membrane
assembly, memory and learning, and calcium ion transport.
The PCC and MTG seem to be mainly involved in signaling
and antiapoptotic pathways. All these processes have been
previously associated with AD [27–33]. It is possible that,
mainly, defense mechanisms are occurring in the PCC and
MTG, although to varying degrees in the two regions. Our
results imply that cell cycle and certain signaling pathways,
along with immune responses, occur in early AD. These
processes include PEDF signaling, delta- and kappa-type
opioid receptors signaling via beta-arrestin, glucocorticoid
receptor signaling, and WNT signaling pathway.
Pigment epithelium-derived factor (PEDF), also known
as serpin F1 (SERPINF1), is amultifunctional secreted protein
that has antiangiogenic, antitumorigenic, and neurotrophic
functions. PEDF induces PPAR-gamma expression which
in turn induces p53, a tumor suppressor gene involved
in cell cycle regulation and apoptosis [34, 35]. PEDF is
downregulated in hypoxic conditions and by𝛽-amyloidwhen
investigated in the retinal cells. It has also been reported to
be affected in AD patients [36]. Maarouf and colleagues [36]
have reported that PEDF’s upregulation in AD brains could
be a defense response since PEDF has anti-inflammatory,
antioxidant, antithrombotic, and neuroprotective properties,
but it could also have a negative function by preventing blood
vessel formation leading to neurodegeneration. Downregu-
lated PEDF has been detected in the plasma of AD patients
and was identified as a potential biomarker for AD [37]. It
was found to be upregulated in the cerebrospinal fluid of
AD patients [36]. The glucocorticoid receptor (GR or GCR)
is also known as NR3C1. The GR regulates genes control-
ling the development, metabolism, and immune response.
The activated GR complex upregulates the expression of
anti-inflammatory proteins in the nucleus or represses the
expression of proinflammatory proteins in the cytosol. The
glucocorticoid receptor is gaining interest since it has a role in
the stress response in the brain. It is implicated in both short-
and long-term adaptations seen in response to stressors and
may be a key factor to the understanding of psychological
disorders [38]. Glucocorticoids have been implicated in
aging, AD, and impaired learning when studied in mice and
rat brains [39, 40]. Many reports have shown the association
of WNT signaling pathway and Alzheimer’s disease [41–43].
It has been implicated in the cause of neurodegeneration in
AD brains.
Cell cycle reentry by neurons has been reported to be the
cause of neuronal death in Alzheimer’s [32, 44–46]. It has
also been shown that neurons definitely die if they begin cell
cycle processes and the cell cycle progression blockers fail
to stop it [44]. However, from the results in Table 3, we find
that cell cycle processes are not very active in the MTG and
PCC regions.This may imply that cell cycle reentry processes
are not early events in AD. We do notice some processes
in the MTG and PCC that may have a role in learning and
memory impairment by disrupting neural plasticity, such
as ephrin signaling and glucocorticoid receptor signaling
[39, 40, 47]. Specifically, glucocorticoids have been associated
with increasing neurotoxicity of reactive oxygen species and
oxidative stress in cells [48, 49]. Recently, BRCA1 has been
reported to be the cause of reentry into the cell cycle [50]. A
very interesting secondary observation was that we did not
find BRCA1 to be differentially expressed in the PCC and
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Table 3: Significant biological processes of the low TO genes that have a larger number of links in the coexpression network of a particular
region.
Number of low Number of genes with high Significant biological processes/pathways
TO genes connectivity in region
204 EC-HIP
115 genes in EC
Regulation of response to stress
Cell adhesion-ephrin signaling
Apoptosis and survival-NO synthesis and signaling
Cell cycle-chromosome condensation in prometaphase
95 genes in HIP
Mitochondrial translational termination
Regulation of protein exit from endoplasmic reticulum
DNA damage-ATM/ATR regulation of G1/S checkpoint
Immune response
140 EC-MTG
84 genes in EC
Cell adhesion
Signal transduction cAMP signaling
Positive regulation of transcription elongation from RNA polII promoter
Regulation of transcription involved in G1 phase (mitotic cell cycle)
Regulation of G2/M transition of mitotic cell cycle
Apoptosis and survival
56 genes in MTG
Negative regulation of stress activated MAPK cascade
Negative regulation of signal transduction
Activation of astroglial cells proliferation by ACM3
Notch signaling pathway
Regulation of lipid metabolism
242 EC-PCC
130 genes in EC Generation of signal involved in cell-cell signaling
Positive regulation of mitotic cell cycle
118 genes in PCC
Proteolysis role of parkin
Immune response IL6 signaling pathway
p53 signaling pathway
Activation of ESR1/SP pathway
125 HIP-MTG
59 genes in HIP
Oxidative phosphorylation
Neuroligin clustering
Gephyrin clustering
Postsynaptic membrane assembly
Cholesterol and sphingolipids transport
66 genes in MTG
Transcription
GTP-XTP metabolism
ATP/ITP metabolism
Osmosensory signaling pathway
Ribonucleotide metabolic process
312 HIP-PCC
145 genes in PCC
Cell adhesion-ephrin signaling
Immune response
Negative adaptation of signaling pathway
174 genes in HIP
Memory and learning
Regulation of dopamine metabolic process
Cognition
Regulation of calcium ion transport
NMDA-dependent postsynaptic long-term potentiation
DNA damage, apoptosis, and survival
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Table 3: Continued.
Number of low Number of genes with high Significant biological processes/pathways
TO genes connectivity in region
158 PCC-MTG
83 genes in PCC
Positive regulation of protein tyrosine kinase activity
Neural plate elongation
Ubiquinone metabolism
PEDF signaling
Cytoskeleton remodeling-RalB regulation pathway
Antiapoptotic TNFs/NF-kB/IAP pathway
77 genes in MTG Glucocorticoid receptor signaling
Positive regulation of transport
ECnet
EC HIP
EC MTG
EC PCC
HIP MTG
HIP PCC
PCC MTG
ECnet
ECnet 
HIPnet
HIPnet
HIPnet
MTGnet
MTGnet
MTGnet
PCCnet 
PCCnet
PCCnet
(1)
(5)
(4)
(3)
(2)
(6)
(EC control samples + EC AD affected samples)
(HIP control samples + HIP AD affected samples)
Common DE genes
Figure 3: Regional coexpression networks construction diagram. Gene coexpression networks built from sets of differentially expressed
genes. EC refers to the entorhinal cortex, HIP is hippocampus, MTG is the middle temporal gyrus, and PCC is posterior cingulate cortex.
For each of the 6 comparisons, the coexpression network was built using the common differentially expressed genes between the two regions
and the samples from that specific region. For instance, when the EC and HIP were being compared, the 2041 common DE genes between
EC and HIP were used to construct the ECnet using the control and the AD affected samples from the EC, while the HIPnet was constructed
on the same set of 2041 DE genes but the control and AD affected samples were from the HIP.This kind of analyses results in 12 coexpression
networks—2 per regional analysis.
International Journal of Alzheimer’s Disease 9
To
po
lo
gi
ca
l o
ve
rla
p 
ge
ne
 ra
nk
in
g
Low
rank
High
rank No overlap
Small overlap No overlap
Small overlap
Complete overlap
Large or could be complete overlap
No overlap
Small overlap
Large or could be complete overlap
Large neighbourhood of gene G1
in 1st region coexpression network
Large neighbourhood of gene G1
in 2nd region coexpression network
Small neighbourhood of gene G1
in 2nd region coexpression network
Small neighbourhood of gene G1
in 1st region coexpression network
Scenario 1
Scenario 2 Scenario 3
Scenario 4
Scenario 5
Scenario 6
Scenario 7
Scenario 8
Scenario 9
Neighbourhoods in both 
networks are small
Figure 4: Ranking of low TO genes. Nine possible scenarios of how neighborhoods overlap when considering neighborhood size and
neighborhood overlap size of a gene, simultaneously, in two regional coexpression networks. Scenarios 1, 2, and 6 occur if the neighborhood
of a gene in both regional networks is large and either they have zero (scenario 1), small (scenario 2), or large/complete (scenario 6) overlap
of their direct neighbors. In scenarios 3, 4, and 5, the gene has a large neighborhood in one network and a small neighborhood in the other
coexpression network. This also could lead to three possible kinds of overlap: zero (scenario 3), small (scenario 4), or large/complete overlap
(scenario 5). Finally, in scenarios 7, 8, and 9, both neighborhoods of the gene are small and could have either zero (scenario 7), small (scenario
8), or large/complete overlap (scenario 9).The scenarios at the top of the figure have a higher rank than the ones at the bottom. Scenarios 1, 2,
and 3 have a higher rank because the gene has either (1) a large neighborhood in both regional networks but small/no overlap of its neighbors
or (2) large difference of its neighborhood in the two regional coexpression networks and no overlap of its neighbors whatsoever. Scenarios
4 and 5 have a large difference in neighborhoods but small or complete overlap of their neighbors. A gene is ranked the highest if it has a
large difference in its neighborhood size and no overlap of its neighbors. This gene is assumed to have high activity (as indicated by the large
neighborhood size) yet different biological roles (as indicated by the zero overlap of its neighborhoods) in the two different regions.
MTG; however, it was differentially expressed in the HIP and
EC regions. It was not selected as a low TO gene, probably
because it did not change its behavior across regions. This
could mean that BRCA1 does not get expressed until much
later in AD progression or probably it only gets expressed in
the most vulnerable regions such as the EC and the HIP.This
observation warrants further investigation.
Another biological process that seemed significant was
oxidative stress. Processes in the PCC and MTG that are
indicative of oxidative stress are stress activated MAPK
cascade, glucocorticoid receptor signaling, nuclear factor-𝜅B
pathway, and regulation of protein tyrosine kinase activity.
The fact that oxidative stress may be an early event in
AD has been reported in many studies [51–53]. Since we
found oxidative stress (OS) as a highlighted process in
early AD, we wanted to identify what neurodegenerative
biomarkers may have been identified so far for OS. For that
purpose, we compared 159 neurodegenerative disease related
genes obtained from the KEGG disease database (using
keywords neurodegenerative, dementia, aging, and cognitive
impairment) with our set of common DE genes between
regions (this set of genes was used to build coexpression
networks). Four genes—AARS (alanyl-tRNA synthetase),
PINK1 (PTEN-inducible kinase 1), SNCB (𝛽-synuclein) and
UBE1 (ubiquitin-activating enzyme E1)—were present in all
six sets of common DE genes. This indicates that all the four
regions had these four genes differentially expressed between
normal controls and AD affected subjects. Of the four genes,
reports have linked PINK1 withOS.The PINK1 gene has been
heavily studied in the contest of Parkinson’s disease [54–56].
It protects against mitochondrial dysfunction during cellular
stress [56]. PINK1 was always downregulated in the MTG
compared to the EC, HIP, and PCC, when affected samples
from each region were compared against each other. PINK1
deficiency has been associated with impaired respiration
and increased production of reactive oxygen species in
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Table 4: Disease associations of sets of lowTOgenes with (extended set) andwithout (primary set) their direct neighbors in the PPI networks.
Region PPI network Disease association of low TO genesand neighbors in PPI net Disease association of low TO genes only
EC-HIP
Cluster 1 enrichment score = 0.96 Cluster 1
Hypertension
Cardiovascular
Arterial disease
Atherosclerosis
Kidney disease
Vascular dementia
Diabetic nephropathy
EC-PCC
Cluster 1 enrichment score = 0.93 Cluster 1
Hyperlipidemia
Ischemic stroke, renal, atherosclerosisCoronary artery disease risk
Cholesterol
Cluster 2 enrichment score = 0.91 Cluster 2
Heart related conditions Cancer
Alzheimer’s disease Macular degeneration
EC-MTG
Cluster 1 enrichment score = 0.89
Insulin, cholesterol
Type 2 diabetes, hypertension
Polycystic ovary syndrome
HIP-PCC Cluster 1 enrichment score = 0.82 Cluster 1
Colon cancer, rectal cancer Crohn’s disease, atherosclerosis, ischemic stroke, renal
PCC-MTG
Cluster 1 enrichment score = 0.99
Type 2 diabetes
Hypertension
Cholesterol
Polycystic ovary syndrome
HIP-MTG
Cluster 1 enrichment score = 1.23
Colon cancer, rectal cancer
Male infertility
The low TO genes are proteins in the region PPI network. Column 1 shows the diseases associated with the low TO proteins and their direct neighbors in the
regional PPI network while column 2 shows the diseases associated with only the low TO genes (without their neighbors). Disease databases used: OMIM
disease, genetic association disease database. Similarity threshold for clustering = 0.80. Results reported only for the clusters with enrichment score 0.8 or
higher. In this analysis, the low TO genes were not divided into 2 groups based on which regional coexpression network they had a higher connectivity in.
the mitochondria [53]. This result further confirmed our
conclusion from our method that OS was truly an early event
in AD.
Based on the results reported here and other researches,
we postulate the following sequence of processes in AD:
oxidative stress → signaling processes and antiapoptotic pro-
cesses involved in cell defense → reentry into cell cycle and
failure of neural plasticity → disruptions in postsynaptic activ-
ities → immune response, apoptotic processes, and multiple
other processes activated → cell death → disruptions in
memory and general brain decline. We think that, initially, the
cellular mechanisms are able to balance the stress activated
proapoptotic and survival pathways; however, as more cellu-
lar machinery disruptions occur, this balance is lost resulting
in eventual cell death.
3.2. Eigenvector Centrality Scores of Low TO Genes. A study
by Goh et al. shows that the vast majority (approximately
78%) of disease genes are nonessential genes, which neither
are hub genes themselves nor do they encode hub proteins
[57]. Therefore, we did not identify hub genes (nodes with
high degree centrality) in our analysis. However, we decided
to measure the eigenvalue centrality of the low TO genes (see
Section 2.4). A hub gene can have a high eigenvector central-
ity but not all genes that have high eigenvector centrality will
be a hub gene. Differences in centrality across two biological
groups have been reported in many scientific papers [58–62].
Specifically, it has been shown that there is a loss of network
connectivity in the brains of AD affected individuals [60–62].
Genes with low topological overlap between affected and
control gene coexpression networks were identified for each
brain region. Then the eigenvector centrality of low TO
genes was computed for the affected and control networks.
If network A has a larger mean eigenvector centrality than
network B, it means that network A has higher connectivity
than network B.
From the results in Table 7, we conclude that the low
TO genes in the AD affected individuals have a lower
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Table 5: Differential connectivity-disease association of the low TO gene modules (low TO proteins and their direct neighbors in the PPI
network).
Number of overlapping
low TO genes
(overlap between coexpression
and PPI network nodes)
Number of low TO genes with
higher connectivity in region
(number of low TO proteins
+ direct neighbors in module)
Diseases clusters
113 low TO genes in EC-HIP
63 + 5 low TO genes in EC Coexp. net (354 proteins)
Cluster 1 enrichment score = 1.31
Arterial disease
Atherosclerosis, generalized blood pressure
Arterial cardiovascular disease
Esophageal varices
Cerebral white matter lesions
Peritoneal transport
45 + 5 low TO genes in HIP Coexp. net (304 proteins)
Cluster 1 enrichment score = 0.8
Stroke, lacunar
Coronary atherosclerosis
Thromboembolism, venous
Stroke, ischemic
94 low TO genes in EC-MTG
39 + 1 low TO genes in MTG Coexp. net (428 proteins) None
54 + 1 low TO genes in EC Coexp. net (325 proteins)
Cluster 1 enrichment score = 1.15
Nephropathy
Stroke
Restenosis
Cluster 2 enrichment score = 0.98
Panencephalitis, subacute sclerosing
Sarcoidosis; tuberculosis
Tuberculosis
Hepatitis B
126 low TO genes in EC-PCC
68 + 3 low TO genes in EC Coexp. net (405 proteins)
Cluster 1 enrichment score = 0.88
Ischemia
Hyperlipidemia
Lipids
Hypercholesterolemia
55 + 3 low TO genes in PCC Coexp. net (468 proteins) None
76 low TO genes in HIP-MTG 36 + 0 low TO genes in HIP Coexp. net (213 proteins)
None
40 + 0 low TO genes in MTGCoexp. net (288 proteins ) None
171 low TO genes in HIP-PCC
94 + 3 low TO genes in HIP Coexp. net (552 proteins)
Cluster 1 enrichment score = 1.31
Colon cancer; rectal cancer
Androgen levels
Hypospadias
74 + 3 low TO genes in PCC Coexp. net (413 proteins)
Cluster 1 enrichment score = 1.31
Coronary atherosclerosis
Glomerulonephritis
Cerebrovascular disease
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Table 5: Continued.
Number of overlapping
low TO genes
(overlap between coexpression
and PPI network nodes)
Number of low TO genes with
higher connectivity in region
(number of low TO proteins
+ direct neighbors in module)
Diseases clusters
87 low TO genes in
PCC-MTG
44 + 1 low TO genes in MTG Coexp. net (644 proteins) None
42 + 1 low TO genes in PCC Coexp. net (357 proteins)
Cluster 1 enrichment score = 0.82
Mood disorder
Smoking behavior
Alcoholism
Suicide
This table provides the diseases linked with differentially connected low TO genes and direct neighbors in the PPI net. Each comparison has the following
format: number of low TO genes with higher connectivity in regional Coexp. net = number of low TO genes with higher connectivity in one brain region
+ number of low TO genes with equal connectivity in both brain regions. For example, in the 113 EC-HIP comparison there are 113 low TO genes of which
63 genes have a higher connectivity in the EC compared to HIP coexpression network, and in addition 5 of them have equal number of connections in both
coexpression networks, whereas 45 genes have a higher connectivity in the HIP with 5 extra genes having equal connectivity in both regions. The number of
proteins and direct neighbors in the PPI net, that is, the module, is given in brackets. In EC HIP, 204 low TO genes⋂ respective pruned PPI net = 113 proteins.
In EC MTG, 140 low TO genes⋂ respective pruned PPI net = 94 proteins. In EC PCC, 242 low TO genes⋂ respective pruned PPI net = 126 proteins. In HIP
MTG, 125 low TO genes⋂ respective pruned PPI net = 76 proteins. In HIP PCC, 312 low TO genes⋂ respective pruned PPI net = 171 proteins. In PCCMTG,
158 low TO genes ⋂ respective pruned PPI net = 87 proteins. This table reveals that MTG is not cardiovascular disease (CVD) associated. When comparing
HIP and PCC, PCC is highly associated with CVD, while HIP is not. When comparing EC and PCC, EC is highly associated with CVD, while PCC is not.
When comparing EC and HIP, both regions are associated with CVD.When comparing EC andMTG, EC is associated with CVD, while MTG is not. Overall,
EC is the brain region mostly associated with CVD. HIP and PCC follow, and PCCmight be more active in CVD than HIP. MTG is least associated with CVD
of all four brain regions.
average eigenvector centrality score compared to those in
normal individuals (control networks). Although in MTG
a higher average eigenvector centrality score was obtained
for the affected group, this result was determined to not be
significant (𝑃 > 0.05). The eigenvector centrality scores
were calculated for all the DE genes in affected and control
networks within each region (results in Table 8). However,
they were not as statistically significant as the low TO genes.
If we take these results to be indicative of the behavior
(in terms of eigenvector centrality values) of the low TO
genes in affected samples, then we can perform the same
analysis across brain regions and determine which region is
more affected than the other. Hence, we analyzed the mean
eigenvector centrality scores of the low TO genes across brain
regions. From Table 9 we can see that the low TO genes
in the MTG had higher average eigenvector centrality score
compared to those in the other brain regions. This implies
that the MTG is the least affected compared to the other
three regions. Since we have hypothesized that because the
MTG is affected later in AD compared to the EC and HIP
the biological processes that are predominant in the MTG
are probably the ones that occur in early AD, the results of
eigenvector centrality scores give us further confidence that
our kind of analysis on low TO genes is fruitful.
3.3. Disease Associations of Genes with Low Topological
Overlap. So far we have shown that low TO genes are useful
in determining the relative disease severity and identifying
some interesting biological processes that may occur in early
AD. Since we found the PINK1 gene, which is associated with
Parkinson’s disease, present in our analyses, we wanted to
identify the diseases, if any, that were associated with the
low TO genes. Using DAVID, we discovered that diseases
such as cardiovascular and renal diseases, bone marrow
transplantation, stroke, and cancer were highly associated
with some sets of low TO genes (Table 4, column 3). Goh
et al. have reported that genes that contribute to a common
disorder have a greater tendency to interact at the protein
level [57]. In order to gain more insights we decided to
look into the protein level of the low TO genes. For further
clarity, we also separated the lowTOgenemodules intowhich
coexpression network they had a higher connectivity in and
identified the associated diseases with these low TO gene
modules (Table 5).
We performed two sets of analyses: (i) analyses of the
protein-protein interaction network built using the set of
common genes between regions and (ii) analyses of the
protein-protein interaction network built by Soler-Lo´pez et
al. [21] (see Figure 1).
3.4. Comparison of Regional mRNA Coexpression Net-
works with Protein-Protein Interaction Networks. Six protein-
protein interaction (PPI) networks (EC-HIP, EC-MTG, EC-
PCC, HIP-MTG, HIP-PCC, and PCC-MTG) were con-
structed as described in Materials and Methods. We refer
to this PPI network as “region PPI network.” We wanted
to identify the diseases associated with the low TO genes
and their direct neighbors in the PPI networks (see Figure 1
(below dashed line)).
The diseases associated with the low TO genes only
(primary set) are shown in column 3 of Table 4 and the
diseases associated with these low TO genes and their direct
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Table 6: Disease association of the pairs of low TO gene modules in Soler-Lo´pez et al.’s AD PPI network.
Number of overlapping
low TO genes
Number of low TO genes with
high connectivity in region
(number of proteins in low TO modules)
Enriched disease clusters
15 EC-HIP
9 + 1 low TO genes in EC (67 proteins)
Cluster 1 enrichment score = 1.88
Arterial disease
Atherosclerosis, generalized blood pressure
Arterial cardiovascular disease
Cerebral white matter lesions
Esophageal varices
Peritoneal transport
5 + 1 low TO genes in HIP (35 proteins) None
21 EC-MTG 12 + 0 low TO genes in EC (60 proteins) None
9 + 0 low TO genes in MTG (125 proteins) None
23 EC-PCC
12 + 0 low TO genes in EC (66 proteins) None
11 + 0 low TO genes in PCC (88 proteins)
Cluster 1 enrichment score = 0.98
Coronary atherosclerosis
Lipoprotein
Cardiovascular disease
Myocardial infarction
Cluster 2 enrichment score = 0.88
Lipoprotein
Myocardial infarction
Coronary artery disease
Atherosclerosis, coronary
12 HIP-MTG
5 + 0 low TO genes in HIP (18 proteins)
Cluster 1 enrichment score = 0.9
Prostate cancer
Breast cancer
Pharmacogenomic
Cancer
7 + 0 low TO genes in MTG (37 proteins) None
27 HIP-PCC
12 + 1 low TO genes in PCC (58 proteins)
Cluster 1 enrichment score = 1.58
Coronary artery disease
Stroke
Crohn’s disease ulcerative colitis
Restenosis
Cluster 2 enrichment score = 0.83
Melanoma
Stomach cancer
Asthma
14 + 1 low TO genes in HIP (95 proteins) None
16 PCC-MTG 6 + 1 low TO genes in PCC (47 proteins) None
9 + 1 low TO genes in MTG (112 proteins) None
Number of low TO genes with high connectivity in regional coexpression network = number of low TO genes with higher connectivity in one brain region +
number of low TO genes with equal connectivity in both brain regions.There are 1704 proteins in ADnet. In ECHIP, 204 low TO genes⋂ADnet = 15 proteins.
In EC MTG, 140 low TO genes⋂ ADnet = 21 proteins. In EC PCC, 242 low TO genes⋂ ADnet = 23 proteins. In HIP MTG, 125 low TO genes⋂ ADnet = 12
proteins. In HIP PCC, 312 low TO genes⋂ ADnet = 27 proteins. In PCC MTG, 158 low TO genes⋂ ADnet = 16 proteins. Disease annotation cluster analysis
was conducted on pairs of exclusive low TO modules (pairs of low TO modules excluding common proteins between module pairs). MTG seems to be least
associated with cardiovascular diseases (CVD).When comparing EC andHIP, EC is highly associated with CVD.When comparing EC and PCC, PCC is highly
associated with CVD. When comparing HIP and PCC, PCC is highly associated with CVD.
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Table 7: Comparison of mean eigenvector centrality scores
(𝐴V𝐸𝑔𝐶) of low TO genes in control and affected coexpression
networks per region.
Region EC PCC HIP MTG
𝐴V𝐸𝑔𝐶 Affected
< control
Affected
< control
Affected
< control
Affected
> control
𝑃 value 1.18𝑒 − 3 7.10𝑒 − 9 7.77𝑒 − 9 3.05𝑒 − 1
Low TO genes were identified between the control and affected networks in
each of the 4 brain regions.The eigenvector centrality scores of these low TO
genes in the control and affected networks were calculated for each region
and their means (𝐴V𝐸𝑔𝐶) were compared. Statistical significance is reached
if 𝑃 value is <0.05.
Table 8: Comparison of mean eigenvector centrality scores
(𝐴V𝐸𝑔𝐶) of DE genes in control and affected coexpression networks
per region.
Region EC PCC HIP MTG
𝐴V𝐸𝑔𝐶 Affected
< control
Affected
< control
Affected
< control
Affected
< control
𝑃 value 6.39𝑒 − 1 2.60𝑒 − 1 2.57𝑒 − 6 1.80𝑒 − 12
Comparison of the average eigenvector centrality scores (𝐴V𝐸𝑔𝐶) of the
differentially expressed genes within each region. Statistical significance is
reached if 𝑃 value is <0.05. In all cases, the mean eigenvector score of the
affected networks was smaller than that of the control networks, although
it was only statistically significant in the hippocampus and middle temporal
gyrus.
neighbors (extended set) in the regionPPI network are shown
in column 2 of Table 4.
For further clarity, the low TO genes identified from the
gene coexpression networks were divided into two groups
based on in which regional gene coexpression network
they had a higher connectivity (see Table 5). Thus, in each
regional comparison, a pair of low TO gene “modules” in
the PPI network was obtained, which included low TO genes
and their corresponding direct and unique neighbors in
the region PPI network. For instance, in the EC-HIP PPI
network, one low TO genemodule consisted of low TO genes
(including their direct neighbors in the EC-HIPPPI network)
whose connectivity is higher in the EC gene coexpression
network and another low TO gene module consisted of
low TO genes (and their direct neighbors in the EC-HIP
PPI network) whose connectivity is higher in the HIP gene
coexpression network. Functional annotation clustering for
diseases in DAVID was implemented for the unique proteins
in the two modules (common proteins between a pair of low
TO modules were removed) in all 6 comparisons. Genetic
association disease database and OMIM disease database
were used with a similarity threshold set to 0.80.
We refer to the largest protein interaction network related
to Alzheimer’s from Soler-Lo´pez et al. [21] as “AD PPI
network.” We analyzed this AD PPI network for disease
associations of the low TO genes. In each of the 6 regional
comparisons, we first identified the set of overlapping low TO
genes between the AD PPI network and our set of low TO
genes. These sets are shown in column 1 of Table 6.
Then as discussed before, pairs of low TO gene modules
were obtained for all the networks. For instance, in the EC-
HIP comparison, the two low TO gene modules consisted
of low TO genes whose connectivity is higher in the EC or
HIP gene coexpression network and their direct neighbors
in the AD PPI network. As before, functional annotation
clustering for diseases in DAVID was implemented for each
pair of low TO gene modules in all 6 comparisons. Both
genetic association disease database and OMIM disease
database were used. Similarity threshold was set to 0.80. Top
four diseases with the lowest 𝑃 values in the clusters with
enrichment score >0.80 are reported in Table 6.
As can be noted from Table 4, the association with car-
diovascular diseases, diabetes, and renal and cancer related
conditions was strong (enrichment score of 0.8 or higher).
Among these diseases, AD and vascular dementia were also
present.This implies that theremay be somedisease biomark-
ers in the set of low TO genes. By comparing the results
obtained from the region PPI networks and the AD PPI
network, we see that there is a consistency in the results from
independent studies. Therefore, analyses by us and others
have shown associations between AD and cardiovascular
diseases and diabetes [14, 63–68]. Interestingly, the PINK1
gene also has been recently associated with heart failure [69].
From the analyses reported here, it is possible that individuals
that already have cardiovascular diseases or diabetes may be
predisposed to Alzheimer’s.
4. Discussion
Relating AD to the fundamental choices of cells as they age
is a critical area of research. The history of AD research
has been hindered by biased hypothesis driven approaches
which have reached their culmination in the recent failure
of numerous clinical trials. In our paper, we present a novel
data driven approach to dissect AD and provide insights to
uncover the initial departure from normal physiology. We
developed a novel method for the comparative analysis of
gene coexpression networks representing different biological
regions. This method is best suited for the analyses of
progressive conditions since the changes across time may be
subtle in most biological conditions. The low TO formula
developed here helps in ranking the genes based on 3 criteria:
how much their neighborhoods overlap, the size of the
neighborhood, and the difference in neighborhood size.
Systems biology methods like this are in high demand
as the differences between many conditions, be they neu-
rodegenerative diseases, brain diseases, different kinds of
cancers, different degrees of disease severity, and so forth, are
very subtle and cannot be easily highlighted using the usual
off-the-shelf clustering or biological pathways identification
algorithms. Many studies investigate only the genes that are
unique to a condition, in order to analyze how different
the conditions are. However, we hypothesize that even the
genes that are common between conditions (conditions can
be physiological, treatment, or time) can contribute to the
differences between conditions either by invoking different
International Journal of Alzheimer’s Disease 15
Table 9: Comparison of mean eigenvector centrality scores (𝐸𝑔𝐶
𝑒
) of low TO genes between brain regions.
𝐸𝑔𝐶
𝑒
EC < PCC EC <HIP EC <MTG PCC <HIP PCC <MTG HIP <MTG
𝑃 value 9.50𝑒 − 6 1.22𝑒 − 7 2.20𝑒 − 16 1.42𝑒 − 1 2.15𝑒 − 12 6.331𝑒 − 9
Comparison of the average eigenvector centrality scores of the low TO genes between regions. Statistical significance is reached if 𝑃 value is <0.05.
biological pathways or by invoking the same biological path-
ways to varying degrees. Our differential network analysis
method is applicable to other studies where a sequence of
activities or processes is being determined. For instance, in
our time-dependent analysis of low dose ionizing radiation
studywewere able to show the active biological processes at 3,
8, and 24 hours [12]. Our approach can aid in identifying the
few genes thatmay be the key players in the specific condition
and, therefore, potential biomarkers or therapeutic targets for
that condition.
Due to the oxidative stress hypothesis in AD, therapies
involving antioxidants are obvious. However, clinical trials
with antioxidants—vitamin E, vitamin C, and coenzyme
Q10 (CoQ10)—have failed [53]. This is probably due to late
therapeutic intervention. One idea would be to study the
effects of antioxidants on different AD affected brain regions
in animal models. The comparison of regions can be done
using our method of analyses.
Although ours is not the first study to conclude that
oxidative stress may be an early event in AD, it is the first
that has arrived at this conclusion using an unbiased means
of analyses of high throughput genomic data. Our suggestion
of the possible sequence of phenomenon in AD is based on
the results obtained in our analyses. Along with increased
oxidative stress, we think abnormal lipid metabolism may
also be an early event inADpathology. Research investigating
whether lipid metabolism is an early event in AD pathogen-
esis is necessary. The system level observations obtained in
this study can have multiple alternative explanations as the
processes present in early AD and neuronal degeneration
are not fully understood. However, the results allow us to
posit testable hypotheses for further investigation.Our results
show that since BRCA1 gets significantly expressed in the
EC and HIP, but not in the MTG and PCC, and it has been
reported to make neurons begin cell cycle, cell cycle reentry
is not an early event. Therefore, our results contradict the
reports that cell cycle is an early event. It precedes amyloid-
𝛽 plaques and neurofibrillary tangles; however, it is not what
triggers the cascade of neurodegeneration in AD.
We chose only to use the common DE genes in the
construction of the PPI network as we wanted to be able to
compare the results from our coexpression network analyses.
We had indications from gene analysis (DE genes or the com-
mon DE genes between regions) that certain diseases were
overrepresented, such as cardiovascular diseases, diabetes,
and cancer. Moreover, it is believed that posttranscriptional
modifications and protein interactions can provide a better
understanding of a condition as compared to only mRNA
expression profiles. This is why we wanted to include PPI
networks but restrict them to include only our set of seed
genes as much as possible, since our set of seed genes
were selected based on AD samples and were, therefore,
AD relevant (kind of create an AD PPI network based on
our set of DE genes). Else, PPI networks can have 10,000
or more nodes/proteins and would no longer be restricted
to AD analyses. In our report we also showed links to
other diseases by analyzing the neighborhood of the low
TO genes in two independent protein interaction networks.
This could imply that certain diseases may predispose an
individual to Alzheimer’s disease. We have shown links to
cardiovascular diseases in our previous report involving gene
module detection and transcription factor identification in
ADmicroarray data [14]. Based on such evidence, we believe
large randomized trials should be conducted on investigating
whether diseases such as diabetes and cardiovascular diseases
predispose an individual to AD.
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